Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People between 18 and 70 years old, of any gender
- People who have been diagnosed with ulcerative colitis according to international guidelines, where other conditions such as radiation-related bowel disease, infectious bowel disease, or tumour-related diseases have been ruled out
- People whose ulcerative colitis has been assessed as moderate to severe based on a scoring system called the Mayo score
- People who have not used any medications or had surgery during the follow-up period that could affect how well a biologic treatment appears to be working
Who may not be able to join:
- People with unstable blood pressure or circulation problems
- People with significant liver or kidney damage, including certain elevated liver enzyme levels or reduced kidney function (confirm with trial site for specific thresholds)
- People who are allergic to either of the two medications being studied (infliximab or vedolizumab)
- People whose main condition is a cancerous tumour of the digestive system
- People who currently have serious or uncontrolled conditions affecting the blood, digestive system, metabolism, hormones, lungs, heart, nervous system, or mental health
- Women who are pregnant, breastfeeding, or who plan to become pregnant
- People currently infected with certain infectious diseases, including hepatitis B, hepatitis C, syphilis, HIV/AIDS, or tuberculosis
- People who are unable to attend regular follow-up appointments and laboratory tests
- People whom the trial investigators consider unsuitable for the study for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Min Chen, Xijing Hospital of Digestive Diseases
Phone: 0086 + 02984771535
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinical remission rates and endoscopic remission rates at 14 weeks, 30 weeks, 52 weeks, and 2 years after first-line biologics treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.